PRESS RELEASEChelsea delivers five prototype AIC readers to Quotient Diagnostics Diabetes is a condition already affecting nearly 200 million people. Diabetics can live long and healthy lives if they stay in close control of their condition. Quotient Diagnostics has developed a technology that will revolutionize how it is monitored and managed. Working with Chelsea Technologies Group they have produced an instrument to provide an on-the-spot reading of glycated haemoglobin, a vital indicator of a diabetic's condition, known as the A1C test. Most A1C tests require a larger blood sample to be taken and sent away to a lab for analysis. The Quotient solution will make it easy, low cost and quick but just as accurate. Chelsea Technologies Group worked closely with Quotient to supply five prototype systems capable of demonstrating the feasibility of a combined fluorescence and absorbance measurement for the test. Contact
Ellen Keegan for more information
|
